✓ Translated by DotMD AI Clinical Council Source: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40379410 ↗

Phase III Randomized Trial: Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study (N = 172)

Original Paper Title: “Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 172
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Five-year patient-reported normal tissue effects suggest 26 Gy/5Fr/1-week hypofractionation is safe for breast cancer patients requiring adjuvant axillary radiotherapy.
  • Study Design & Sample: Phase III Randomized Trial published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (N = 172 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2025), this phase iii randomized trial evaluating 172 human participants investigated: FAST-Forward showed that 26 Gray (Gy) in 5 fractions (Fr) over one week adjuvant radiotherapy to breast or chest wall was as safe and effective as a three-week schedule (40 Gy/15Fr) for early breast cancer. Key clinical takeaway: Five-year patient-reported normal tissue effects suggest 26 Gy/5Fr/1-week hypofractionation is safe for breast cancer patients requiring adjuvant axillary radiotherapy.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025-06-15; N = 172; Rigor 82/100): Five-year patient-reported normal tissue effects suggest 26 Gy/5Fr/1-week hypofractionation is safe for breast cancer patients requiring adjuvant axillary radiotherapy.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: nasal-cancer → Condition: neurofibromatosis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40379410: Phase III Randomized Trial: Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study (N = 172)

3 of 3 Free Questions Remaining